Gemina Financial Statements From 2010 to 2024
| GLABF Stock | USD 0.55 0.01 1.79% |
Check Gemina Laboratories financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gemina Laboratories' main balance sheet or income statement drivers, such as , as well as many indicators such as . Gemina financial statements analysis is a perfect complement when working with Gemina Laboratories Valuation or Volatility modules.
Gemina |
Gemina Laboratories OTC Stock Operating Margin Analysis
Gemina Laboratories' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Gemina Laboratories Operating Margin | 979.18 % |
Most of Gemina Laboratories' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gemina Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Gemina Laboratories has an Operating Margin of 979%. This is 2891.28% lower than that of the Healthcare sector and notably lower than that of the Biotechnology industry. The operating margin for all United States stocks is notably lower than that of the firm.
Gemina Laboratories Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Gemina Laboratories's current stock value. Our valuation model uses many indicators to compare Gemina Laboratories value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Gemina Laboratories competition to find correlations between indicators driving Gemina Laboratories's intrinsic value. More Info.Gemina Laboratories is rated # 2 in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Gemina Laboratories' earnings, one of the primary drivers of an investment's value.About Gemina Laboratories Financial Statements
Gemina Laboratories stakeholders use historical fundamental indicators, such as Gemina Laboratories' revenue or net income, to determine how well the company is positioned to perform in the future. Although Gemina Laboratories investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gemina Laboratories' assets and liabilities are reflected in the revenues and expenses on Gemina Laboratories' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gemina Laboratories. Please read more on our technical analysis and fundamental analysis pages.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. Gemina Laboratories operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Gemina OTC Stock
Gemina Laboratories financial ratios help investors to determine whether Gemina OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gemina with respect to the benefits of owning Gemina Laboratories security.